Hutchmed (China) Limited (HCM) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED’s partner Takeda has received a positive CHMP opinion for fruquintinib, a potential new metastatic colorectal cancer treatment in the EU, marking a significant step towards marketing authorization. This recommendation is based on the FRESCO-2 Phase III clinical trial results and, if approved, fruquintinib will be the first novel targeted therapy for this condition in the EU in over a decade. Fruquintinib, having shown a profound impact on patients in China and the U.S., now awaits the European Commission’s final decision.
For further insights into HCM stock, check out TipRanks’ Stock Analysis page.